From: A three-stage, deep learning, ensemble approach for prognosis in patients with Parkinson’s disease
Method | MAPE | MAE | MSE | r | R2 |
---|---|---|---|---|---|
Ensemble approach | 18.36% (11.74%, 24.98%) | 4.70 (3.56, 5.84) | 34.53 (18.81, 50.25) | 0.84 | 0.71 |
DaTscan + MDS-UPDRS-III + Clinical Information | 19.89% (12.48%, 27.30%) | 5.04 (3.78, 6.29) | 40.41 (22.09, 58.74) | 0.81 | 0.66 |
DaTscan + MDS-UPDRS-III (No Clinical Information) | 19.89% (13.63%, 26.15%) | 5.22 (4.09, 6.35) | 39.37 (24.48, 54.25) | 0.81 | 0.66 |
MDS-UPDRS-III + Clinical (No DaTscan Information) | 26.33% (17.76%, 34.91%) | 6.63 (5.11, 8.14) | 65.85 (36.14, 95.57) | 0.64 | 0.41 |
DaTscan + Clinical (No MDS-UPDRS-III Information) | 35.48% (22.50%, 48.46%) | 9.15 (6.90, 11.39) | 131.71 (73.60, 189.81) | 0.04 (n.s.) | 0.00 |